CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock (English only)
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that its Chief Executive Officer, Alexander Zehnder, recently purchased 50,000 common shares of CureVac stock.